Download TUMORS OF THE SALIVARY GLANDS

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
TUMORS OF THE SALIVARY
GLANDS
TUMORS OF THE SALIVARY GLANDS
MASSES
DIFFERENTIAL DIAGNOSIS OF A SALIVARY
GLAND MASS:
INFLAMMATION (PAROTIDITIS) –
MUMPS –
CALCULI –
NEOPLASM –

TUMORS OF THE SALIVARY GLANDS
INCIDENCE: 3/100,000 
3%ALL BODY TUMORS 
LOCATION OF SALIVARY GLAND TUMORS: 85% 
PAROTID, 10% SUBMANDIBULAR, 1% SUBLINGUAL, 45% MINOR SALIVARY GLANDS
TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
80%OF ALL BENIGN LESIONS ARISE IN THE
LATERAL (TAIL) OF THE PAROTID GLAND.
SUPERFICIAL PAROTIDECTOMY WITH 
PRESERVATION OF THE FACIAL NERVE
TOTAL SUBMANDIBULAR AND SUBLINGUAL
GLAND RESECTION


TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
PLEOMORPHIC ADENOMA
BENIGN MIXED TUMOR

MYOEPITHELIAL AND EPIDERMOID CELL ORIGIN
MOST COMMON NEOPLASM IN THE PAROTID
GLAND ACCOUNTS FOR 65% OF ALL OF THE
PAROTID TUMORS.


TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
PLEOMORPHIC ADENOMA
TREATMENT: WIDE RESECTION OF THE TUMOR
AVOID SHELLING OUT THE LESION


RECURRENCE: PRIMARY DUE TO INADEQUATE
RESECTION

LESIONS ARE MORE AGGRESSIVE WHEN THEY
RECUR.

TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
WARTHIN’S TUMOR (ADENOLYMPHOMA)
SECOND MOST COMMON PAROTID TUMOR
MALE : FEMALE 5 : 1
BILATERAL 10%



PRIMARILY LOCATED IN THE LATERAL GLAND HOWEVER
MULTICENTRICITY IS DESCRIBED.
PEA SOUP BROWN MUCOID MATERIAL ON SECTIONING


TREATMENT: LATERAL OR TOTAL GLANDULAR RESECTION

TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
WARTHIN’S TUMOR (ADENOLYMPHOMA)
90%CURED WITH RESECTION

10%RECUR DUE TO MULTICENTRICITY OR
INADEQUATE RESECTION.

TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
ONCOCYTOMA
PRINCIPALLY A PAROTID GLAND TUMOR
5TH DECADE


PROBABLY DUE TO HYPERPLASIA FROM AGING
>1%SALIVARY GLAND TUMORS

CYSTIC COMPONENT HAS BEEN IDENTIFIED.


TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
BASAL CELL ADENOMA
COMMON IN THE LATERAL PAROTID AND THE
SUBMUCOSAL GLANDS IN THE UPPER LIP.
TREATMENT: LATERAL OR TOTAL GLANDULAR
RESECTION.


TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
HEMANGIOMA
50%OF ALL PAROTID TUMORS IN CHILDREN

TREATMENT: ENVOLUTION BY THE AGE OF 5 IS
COMMON
CN VII: SUPERFICIAL LOCATION IN CHILDREN 
THUS OPERATIVE INTERVENTION SHOULD BE
AVOIDED AND LET ENVOLUTION PROCEED
UNLESS THERE IS UNCONTROLLED BLEEDING.
STEROID THERAPY


TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
LIPOMA
4%OF ALL PAROTID TUMORS 
MALE PREDOMINANCE 
4-5%TH DECADE 
TREATMENT: LATERAL OR TOTAL GLANDULAR
RESECTION

TUMORS OF THE SALIVARY GLANDS
BENIGN MASSES
MYXOMA
SLOW GROWING
INFILTRATIVE


TREATMENT: WIDE RESECTION OR TOTAL
GLANDULAR REMOVAL

TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
PROGNOSIS: PALATE > PAROTID > SUBMANDIBULAR /
SUBLINGUAL GLAND
5TH-6TH DECADE


RATE OF GROWTH DOES NOT CORRELATE WITH THE
DEGREE OF MALIGNANCY
LUNG/BONE: PRIMARY METASTATIC SITES

PRIOR RADIOTHERAPY INCREASES THE RISK OF A
SALIVARY GLAND MALIGNANCY.


TUMORS OF THE SALIVARY GLANDS MALIGNANT
MASSES
MUCOEPIDERMOID CARCINOMA
MUCOUS AND EPIDERMOID CELL ORIGIN 
6%OF ALL PAROTID TUMORS - MOST COMMON
MALIGNANCY
65%FOUND IN THE PAROTID GLAND 
18%OF ALL MALIGNANT TUMORS OF THE 
SALIVARY GLANDS

TUMORS OF THE SALIVARY GLANDS MALIGNANT
MASSES
MUCOEPIDERMOID CARCINOMA
LOW, INTERMEDIATE AND HIGH GRADES
4-6TH DECADE


8%CN VII INVOLVEMENT AT THE TIME OF
PRESENTATION
10%LYMPH NODE METASTASIS


TUMORS OF THE SALIVARY GLANDS MALIGNANT MASSES
MUCOEPIDERMOID CARCINOMA
TREATMENT: TOTAL GLANDULAR RESECTION
+/- NECK NODE DISSECTION

CN VII: SPARE NERVE UNLESS INVOLVED WITH
TUMOR.

POSTOPERATIVE RADIOTHERAPY DEPENDING
ON MARGINS, EXTRACAPSULAR EXTENSION
FROM LYMPH NODES, PERINEURAL
INVOLVEMENT, OR INVOLVEMENT OF
SURROUNDING STRUCTURES

TUMORS OF THE SALIVARY GLANDS MALIGNANT
MASSES
MUCOEPIDERMOID CARCINOMA
RECURRENCE RATE 15-25%, USUALLY DUE TO
INADEQUATE RESECTION.
WHEN MUCUOEPIDERMOID CARCINOMA IS 
LOCATED IN THE SUBMANDIBULAR GLAND, THE
TUMOR IS MORE AGGRESSIVE.
RARELY INVOLVES THE SUBLINGUAL GLAND


TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
ADENOID CYSTIC CARCINOMA (CYLINDROMA)
MOST COMMON MALIGNANT TUMOR OF THE
SUBMANDIBULAR GLANDS AND THE SECOND
MOST COMMON PAROTID MALIGNANCY
25-30%CN VII PARALYSIS/PARESIS ON
PRESENTATION
PERINEURAL INVASION IS COMMON


GRAY PINK WITH CRIBRIFORM HISTOLOGY


TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
ADENOID CYSTIC CARCINOMA (CYLINDROMA)
UNPREDICTABLE TUMOR

SLOW GROWING, HOWEVER, RELENTLESS
DISEASE
LUNG METASTASIS COMMON


LYMPH NODE INVOLVEMENT NOT COMMON

TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
ADENOID CYSTIC CARCINOMA (CYLINDROMA)
TREATMENT: SURGICAL RESECTION OF THE 
GLAND WITH POSSIBLE NERVE RESECTION IF
INVOLVED
POSTOPERATIVE RADIOTHERAPY

MALIGNANT PLEOMORPHIC ADENOMA
(MALIGNANT MIXED TUMOR
OR CARCINOMA EX PLEOMORPHIC ADENOMA)
ETIOLOGY: MALIGNANT TRANSFORMATION OF A
PLEOMORPHIC ADENOMA
5-6TH DECADE 
AVERAGE DURATION OF THE LESION IS 
PRESENT 10 YEARS BEFORE BEING
DIAGNOSED
TREATMENT: GLANDULAR RESECTION WITH 
NERVE RESECTION IF INVOLVED WITH TUMOR

ACINOUS (ACINIC) CELL CARCINOMA
LOW, INTERMEDIATE AND HIGH GRADE 
INTRAVASCULAR EXTENSION 
3RD-6TH DECADE 
METASTASIS TO THE LUNG AND BONE (VERTEBRAE)
TREATMENT: GLANDULAR RESECTION 
RADIOTHERAPY IS NOT EFFECTIVE 

TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
SQUAMOUS CELL CARCINOMA
IS IT A METASTATIC LESION? 
1/3HAVE FACIAL NERVE INVOLVEMENT AT THE
TIME OF PRESENTATION
MALE > FEMALE

6TH DECADE 
TOTAL GLANDULAR RESECTION
10YEAR SURVIVAL: 45% 


ADENOCARCINOMA
USUALLY FIXED TO THE SURROUNDING STRUCTURES 
MALE > FEMALE 
3RD - 6TH DECADE 
22%FACIAL NERVE INVOLVEMENT AT THE TIME OF PRESENTATION
25%METASTASIS AT THE TIME OF PRESENTATION 
GLANDULAR RESECTION WITH NERVE RESECTION IF INVOLVED 
WITH TUMOR
NECK DISSECTION 
POSTOPERATIVE RADIOTHERAPY 

TUMORS OF THE SALIVARY GLANDS
MALIGNANT MASSES
UNDIFFERENTIATED CARCINOMA
7TH-8TH DECADE 
33%FACIAL NERVE INVOLVEMENT AT THE TIME
OF PRESENTATION
HIGHLY MALIGNANT

TREATMENT: GLANDULAR RESECTION, NECK 
DISSECTION, POSTOPERATIVE RADIOTHERAPY
NERVE RESECTION IF INVOLVED


TUMORS OF THE SALIVARY GLANDS
COMPLICATIONS OF SURGICAL INTERVENTION
ORAL FISTULAS 
FACIAL NERVE INJURY 
LOSS OF EAR SENSATION 
FREY’S SYNDROME (GUSTATORY SWEATING)
SKIN NECROSIS 
